Ricevi le ultime notizie sulle azioni Armata Pharmaceuticals con aggiornamenti su tendenze di mercato, dati finanziari e analisi di Benzinga. Rimani informato sulle performance di ARMP

Ultime notizie per

ARMATA PHARMACEUTICALS INC

Armata Pharmaceuticals

Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.

Armata Pharmaceuticals, Inc. Common Stock

Armata Pharmaceuticals Inc

Press Releases

Armata Pharmaceuticals Announces that CEO Dr. Deborah Birx Will Deliver a Presentation at the 5th Annual Phage Futures Annual Meeting

Armata Pharmaceuticals Announces Encouraging Results from the Phase 2 Tailwind Study of Inhaled AP-PA02 in Non-Cystic Fibrosis Bronchiectasis Subjects with Chronic Pulmonary Pseudomonas aeruginosa Infection

Armata Pharmaceuticals Announces that CEO Dr. Deborah Birx Will Deliver a Presentation at the 7th Annual Bacteriophage Therapy Summit

Armata Pharmaceuticals Announces $10 Million Secured Credit Agreement with Innoviva

Earnings

Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2024 Results and Provides Corporate Update

Armata Pharmaceuticals Receives $4.65 Million of Additional Non-Dilutive Award Funding from the U.S. Department of Defense to Support Ongoing diSArm Clinical Trial of AP-SA02

Armata Pharmaceuticals Announces First Quarter 2025 Results and Provides Corporate Update

Armata Pharmaceuticals Announces Positive Topline Data from the Phase 1b/2a diSArm Study of Intravenously Administered AP-SA02 in Complicated Staphylococcus aureus Bacteremia

This $13M Biotech Has $40M in Pentagon Funding – Here's Why BiomX Could Be Biotech's Best-Kept Secret

Armata Pharmaceuticals Announces Second Quarter 2025 Results and Provides Corporate Update

ARMP

INVA

PHGE

Acumen Pharmaceuticals, Inc. - Common Stock

Acumen Pharmaceuticals

Adagene Inc. - ADS, each representing 1.25 ordinary shares

Adagene

Anixa Biosciences

Atossa Therapeutics

Atara Biotherapeutics, Inc. - Common Stock

Atara Biotherapeutics

Biomea Fusion

Celularity

Coya Therapeutics

CervoMed

Elutia

Entera Bio

ESSA Pharma

Immunic

Inovio Pharmaceuticals, Inc. - Common Stock

Inovio Pharmaceuticals

IO Biotech

Invivyd

Macrogenics

OKYO Pharma

Oncolytics Biotech

Quince Therapeutics

Sera Prognostics, Inc. - Class A Common Stock

Sera Prognostics

Skye Bioscience

Surrozen

Vistagen Therapeutics, Inc. - Common Stock

Vistagen Therapeutics

XBiotech

HC Wainwright & Co.

Axovant Gene Therapies Ltd. - Common Shares

Comments

Armata Pharmaceuticals Notizie sulle azioni

Notizie

Ultime notizie per

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO